» Articles » PMID: 39570879

Anaplerotic Filling in Heart Failure: a Review of Mechanism and Potential Therapeutics

Overview
Journal Cardiovasc Res
Date 2024 Nov 21
PMID 39570879
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure (HF) is a complex syndrome and a leading cause of mortality worldwide. While current medical treatment is based on known pathophysiology and is effective for many patients, the underlying cellular mechanisms are poorly understood. Energy deficiency is a characteristic of HF, marked by complex alterations in metabolism. Within the tricarboxylic acid cycle, anaplerosis emerges as an essential metabolic process responsible for replenishing lost intermediates, thereby playing a crucial role in sustaining energy metabolism and consequently cardiac function. Alterations in cardiac anaplerosis are commonly observed in HF, demonstrating potential for therapeutic intervention. This review discusses recent advances in understanding the anaplerotic adaptations that occur in HF. We also explore therapeutics that can directly modulate anaplerosis or are likely to confer cardioprotective effects through anaplerosis, which could potentially be implemented to rescue the failing heart.

References
1.
. Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J. 1999; 20(1):70-6. DOI: 10.1053/euhj.1998.1271. View

2.
Bozkurt B, Coats A, Tsutsui H, Abdelhamid C, Adamopoulos S, Albert N . Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal.... Eur J Heart Fail. 2021; 23(3):352-380. DOI: 10.1002/ejhf.2115. View

3.
Russell 3rd R, Taegtmeyer H . Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest. 1991; 87(2):384-90. PMC: 295088. DOI: 10.1172/JCI115008. View

4.
Mancini M, Rengo F, Lingetti M, Sorrentino G, Nolfe G . Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung. 1992; 42(9):1101-4. View

5.
Gillingham M, Heitner S, Martin J, Rose S, Goldstein A, El-Gharbawy A . Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017; 40(6):831-843. PMC: 6545116. DOI: 10.1007/s10545-017-0085-8. View